Literature DB >> 29907549

Real-world evidence in safety assessment of new treatments.

Karin E Smedby1, Sandra Eloranta2.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 29907549     DOI: 10.1016/S2352-3026(18)30073-5

Source DB:  PubMed          Journal:  Lancet Haematol        ISSN: 2352-3026            Impact factor:   18.959


× No keyword cloud information.
  3 in total

Review 1.  Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Vishal Bhatnagar; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; Nicole Gormley; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Yok Lam Kwong; Richard F Little; Matthew J Matasar; Maria-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Abhilasha Nair; Loretta Nastoupil; Kaye Robertson; Surbhi Sidana; Karin E Smedby; Pieter Sonneveld; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2022-05       Impact factor: 30.153

2.  Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group.

Authors:  Michael Leisch; Michael Pfeilstöcker; Reinhard Stauder; Sonja Heibl; Heinz Sill; Michael Girschikofsky; Margarete Stampfl-Mattersberger; Christoph Tinchon; Bernd Hartmann; Andreas Petzer; Martin Schreder; David Kiesl; Sonia Vallet; Alexander Egle; Thomas Melchardt; Gudrun Piringer; Armin Zebisch; Sigrid Machherndl-Spandl; Dominik Wolf; Felix Keil; Manuel Drost; Richard Greil; Lisa Pleyer
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

Review 3.  Real-world evidence and product development: Opportunities, challenges and risk mitigation.

Authors:  Poobalan Naidoo; Célia Bouharati; Virendra Rambiritch; Nadina Jose; Sumanth Karamchand; Robert Chilton; Rory Leisegang
Journal:  Wien Klin Wochenschr       Date:  2021-04-09       Impact factor: 1.704

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.